267 research outputs found
Outcomes of the Botswana national HIV/AIDS treatment programme from 2002 to 2010: a longitudinal analysis
Background Short-term mortality rates among patients with HIV receiving antiretroviral therapy (ART) in sub-
Saharan Africa are higher than those recorded in high-income countries, but systematic long-term comparisons have
not been made because of the scarcity of available data. We analysed the eff ect of the implementation of Botswana’s
national ART programme, known as Masa, from 2002 to 2010.
Methods The Masa programme started on Jan 21, 2002. Patients who were eligible for ART according to national
guidelines had their data collected prospectively through a clinical information system developed by the Botswana
Ministry of Health. A dataset of all available electronic records for adults (≥18 years) who had enrolled by April 30,
2010, was extracted and sent to the study team. All data were anonymised before analysis. The primary outcome was
mortality. To assess the eff ect of loss to follow-up, we did a series of sensitivity analyses assuming varying proportions
of the population lost to follow-up to be dead.
Findings We analysed the records of 126 263 patients, of whom 102 713 had documented initiation of ART. Median
follow-up time was 35 months (IQR 14–56), with a median of eight follow-up visits (4–14). 15 270 patients were
deemed lost to follow-up by the end of the study. 63% (78 866) of the study population were women; median age at
baseline was 34 years for women (IQR 29–41) and 38 years for men (33–45). 10 230 (8%) deaths were documented
during the 9 years of the study. Mortality was highest during the fi rst 3 months after treatment initiation at 12·8 deaths
per 100 person-years (95% CI 12·4–13·2), but decreased to 1·16 deaths per 100 person-years (1·12–1·2) in the second
year of treatment, and to 0·15 deaths per 100 person-years (0·09–0·25) over the next 7 years of follow-up. In each
calendar year after the start of the Masa programme in 2002, average CD4 cell counts at enrolment increased (from
101 cells/μL [IQR 44–156] in 2002, to 191 cells/μL [115–239] in 2010). In each year, the proportion of the total enrolled
population who died in that year decreased, from 63% (88 of 140) in 2002, to 0·8% (13 of 1599) in 2010. A sensitivity
analysis assuming that 60% of the population lost to follow-up had died gave 3000 additional deaths, increasing
overall mortality from 8% to 11–13%.
Interpretation The Botswana national HIV/AIDS treatment programme reduced mortality among adults with HIV to
levels much the same as in other low-income or middle-income countries
Recommended from our members
Risk Factors for Symptomatic Hyperlactatemia and Lactic Acidosis Among Combination Antiretroviral Therapy-Treated Adults in Botswana: Results from a Clinical Trial
Nucleoside analogue reverse transcriptase inhibitors are an integral component of combination antiretroviral treatment regimens. However, their ability to inhibit polymerase-γ has been associated with several mitochondrial toxicities, including potentially life-threatening lactic acidosis. A total of 650 antiretroviral-naive adults (69% female) initiated combination antiretroviral therapy (cART) and were intensively screened for toxicities including lactic acidosis as part of a 3-year clinical trial in Botswana. Patients were categorized as no lactic acidosis symptoms, minor symptoms but lactate <4.4 mmol/liter, and symptoms with lactate ≥ 4.4 mmol/liter [moderate to severe symptomatic hyperlactatemia (SH) or lactic acidosis (LA)]. Of 650 participants 111 (17.1%) developed symptoms and/or laboratory results suggestive of lactic acidosis and had a serum lactate drawn; 97 (87.4%) of these were female. There were 20 events, 13 having SH and 7 with LA; all 20 (100%) were female (p<0.001). Cox proportional hazard analysis limited to the 451 females revealed that having a higher baseline BMI was predictive for the development of SH/LA [aHR=1.17 per one-unit increase (1.08-1.25), p<0.0001]. Ordered logistic regression performed among all 650 patients revealed that having a lower baseline hemoglobin [aOR=1.28 per one-unit decrease (1.1-1.49), p=0.002] and being randomized to d4T/3TC-based cART [aOR=1.76 relative to ZDV/3TC (1.03-3.01), p=0.04] were predictive of the symptoms and/or the development of SH/LA. cART-treated women in sub-Saharan Africa, especially those having higher body mass indices, should receive additional monitoring for SH/LA. Women presently receiving d4T/3TC-based cART in such settings also warrant more intensive monitoring
Time for gender mainstreaming in editorial policies
The HIV epidemic has been continuously growing among women, and in some parts of the world, HIV-infected women outnumber men. Women's greater vulnerability to HIV, both biologically and socially, influences their health risk and health outcome. This disparity between sexes has been established for other diseases, for example, autoimmune diseases, malignancies and cardiovascular diseases. Differences in drug effects and treatment outcomes have also been demonstrated
HIV-1 Subtype C-Infected Individuals Maintaining High Viral Load as Potential Targets for the “Test-and-Treat” Approach to Reduce HIV Transmission
The first aim of the study is to assess the distribution of HIV-1 RNA levels in subtype C infection. Among 4,348 drug-naïve HIV-positive individuals participating in clinical studies in Botswana, the median baseline plasma HIV-1 RNA levels differed between the general population cohorts (4.1–4.2 log10) and cART-initiating cohorts (5.1–5.3 log10) by about one log10. The proportion of individuals with high (≥50,000 (4.7 log10) copies/ml) HIV-1 RNA levels ranged from 24%–28% in the general HIV-positive population cohorts to 65%–83% in cART-initiating cohorts. The second aim is to estimate the proportion of individuals who maintain high HIV-1 RNA levels for an extended time and the duration of this period. For this analysis, we estimate the proportion of individuals who could be identified by repeated 6- vs. 12-month-interval HIV testing, as well as the potential reduction of HIV transmission time that can be achieved by testing and ARV treating. Longitudinal analysis of 42 seroconverters revealed that 33% (95% CI: 20%–50%) of individuals maintain high HIV-1 RNA levels for at least 180 days post seroconversion (p/s) and the median duration of high viral load period was 350 (269; 428) days p/s. We found that it would be possible to identify all HIV-infected individuals with viral load ≥50,000 (4.7 log10) copies/ml using repeated six-month-interval HIV testing. Assuming individuals with high viral load initiate cART after being identified, the period of high transmissibility due to high viral load can potentially be reduced by 77% (95% CI: 71%–82%). Therefore, if HIV-infected individuals maintaining high levels of plasma HIV-1 RNA for extended period of time contribute disproportionally to HIV transmission, a modified “test-and-treat” strategy targeting such individuals by repeated HIV testing (followed by initiation of cART) might be a useful public health strategy for mitigating the HIV epidemic in some communities
Strengthening Healthcare Capacity Through a Responsive, Country-Specific, Training Standard: The KITSO AIDS Training Program’s Sup-port of Botswana’s National Antiretroviral Therapy Rollout
In parallel with the rollout of Botswana’s national antiretroviral therapy (ART) program, the Botswana Ministry of Health established the KITSO AIDS Training Program by entering into long-term partnerships with the Botswana–Harvard AIDS Institute Partnership for HIV Research and Education and others to provide standardized, country-specific training in HIV/AIDS care. The KITSO training model has strengthened human capacity within Botswana’s health sector and been indispensable to successful ART rollout. Through core and advanced training courses and clinical mentoring, different cadres of health care workers have been trained to provide high-quality HIV/AIDS care at all ART sites in the country. Continuous and standardized clinical education will be crucial to sustain the present level of care and successfully address future treatment challenges
Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism
This is a non-final version of an article published in final form in AIDS. 28 November 2012 - Volume 26 - Issue 18 - p 2275–2284Objectives: To characterize the nature and dynamics of the neutralizing antibody
(NAb) response and escape in chronically HIV-2 infected patients.Methods: Twenty-eight chronically infected adults were studied over a period of 1-4
years. The neutralizing activity of plasma IgG antibodies against autologous and
heterologous primary isolates was analyzed using a standard assay in TZM-bl cells. Coreceptor
usage was determined in GHOST cells. The sequence and predicted 3Dstructure
of the C2V3C3 Env region were determined for all isolates.Results: Only 50% of the patients consistently produced IgG NAbs to autologous and
contemporaneous virus isolates. In contrast, 96% of the patients produced IgG
antibodies that neutralized at least two isolates of a panel of six heterologous R5
isolates. Breadth and potency of the neutralizing antibodies were positively associated
with the number of CD4+ T cells and with the titer and avidity of C2V3C3-specific
binding IgG antibodies. X4 isolates were obtained only from late stage disease patients
and were fully resistant to neutralization. The V3 loop of X4 viruses was longer, had a
higher net charge and differed markedly in secondary structure compared to R5 viruses.Conclusions: Most HIV-2 patients infected with R5 isolates produce C2V3C3-specific
neutralizing antibodies whose potency and breadth decreases as the disease progresses.
Resistance to antibody neutralization occurs in late stage disease and is usually
associated with X4 viral tropism and major changes in V3 sequence and conformation.
Our studies support a model of HIV-2 pathogenesis in which the neutralizing antibodies
play a central role and have clear implications for the vaccine field.Fundação para a Ciência e Tecnologia, Portuga
Recommended from our members
Association between Virus-Specific T-Cell Responses and Plasma Viral Load in Human Immunodeficiency Virus Type 1 Subtype C Infection
Virus-specific T-cell immune responses are important in restraint of human immunodeficiency virus type 1 (HIV-1) replication and control of disease. Plasma viral load is a key determinant of disease progression and infectiousness in HIV infection. Although HIV-1 subtype C (HIV-1C) is the predominant virus in the AIDS epidemic worldwide, the relationship between HIV-1C-specific T-cell immune responses and plasma viral load has not been elucidated. In the present study we address (i) the association between the level of plasma viral load and virus-specific immune responses to different HIV-1C proteins and their subregions and (ii) the specifics of correlation between plasma viral load and T-cell responses within the major histocompatibility complex (MHC) class I HLA supertypes. Virus-specific immune responses in the natural course of HIV-1C infection were analyzed in the gamma interferon (IFN-γ)-enzyme-linked immunospot assay by using synthetic overlapping peptides corresponding to the HIV-1C consensus sequence. For Gag p24, a correlation was seen between better T-cell responses and lower plasma viral load. For Nef, an opposite trend was observed where a higher T-cell response was more likely to be associated with a higher viral load. At the level of the HLA supertypes, a lower viral load was associated with higher T-cell responses to Gag p24 within the HLA A2, A24, B27, and B58 supertypes, in contrast to the absence of such a correlation within the HLA B44 supertype. The present study demonstrated differential correlations (or trends to correlation) in various HIV-1C proteins, suggesting (i) an important role of the HIV-1C Gag p24-specific immune responses in control of viremia and (ii) more rapid viral escape from immune responses to Nef with no restraint of plasma viral load. Correlations between the level of IFN-γ-secreting T cells and viral load within the MHC class I HLA supertypes should be considered in HIV vaccine design and efficacy trials
Recommended from our members
Association between Virus-Specific T-Cell Responses and Plasma Viral Load in Human Immunodeficiency Virus Type 1 Subtype C Infection
Virus-specific T-cell immune responses are important in restraint of human immunodeficiency virus type 1 (HIV-1) replication and control of disease. Plasma viral load is a key determinant of disease progression and infectiousness in HIV infection. Although HIV-1 subtype C (HIV-1C) is the predominant virus in the AIDS epidemic worldwide, the relationship between HIV-1C-specific T-cell immune responses and plasma viral load has not been elucidated. In the present study we address (i) the association between the level of plasma viral load and virus-specific immune responses to different HIV-1C proteins and their subregions and (ii) the specifics of correlation between plasma viral load and T-cell responses within the major histocompatibility complex (MHC) class I HLA supertypes. Virus-specific immune responses in the natural course of HIV-1C infection were analyzed in the gamma interferon (IFN-γ)-enzyme-linked immunospot assay by using synthetic overlapping peptides corresponding to the HIV-1C consensus sequence. For Gag p24, a correlation was seen between better T-cell responses and lower plasma viral load. For Nef, an opposite trend was observed where a higher T-cell response was more likely to be associated with a higher viral load. At the level of the HLA supertypes, a lower viral load was associated with higher T-cell responses to Gag p24 within the HLA A2, A24, B27, and B58 supertypes, in contrast to the absence of such a correlation within the HLA B44 supertype. The present study demonstrated differential correlations (or trends to correlation) in various HIV-1C proteins, suggesting (i) an important role of the HIV-1C Gag p24-specific immune responses in control of viremia and (ii) more rapid viral escape from immune responses to Nef with no restraint of plasma viral load. Correlations between the level of IFN-γ-secreting T cells and viral load within the MHC class I HLA supertypes should be considered in HIV vaccine design and efficacy trials
Pregnancy outcomes and birth defects from an antiretroviral drug safety study of women in South Africa and Zambia
OBJECTIVE : To evaluate the safety of combination antiretroviral therapy (ART) in
conception and pregnancy in different health systems.
DESIGN : A pilot ART registry to measure the prevalence of birth defects and adverse
pregnancy outcomes in South Africa and Zambia.
METHODS : HIV-infected pregnant women on ART prior to conception were enrolled
until delivery, and their infants were followed until 1 year old.
RESULTS : Between October 2010 and April 2011, 600 women were enrolled. The
median CD4þ cell count at study enrollment was lower in South Africa than Zambia
(320 vs. 430 cells/ml; P<0.01). The most common antiretroviral drugs at the time of
conception included stavudine, lamivudine, and nevirapine. There were 16 abortions
(2.7%), 1 ectopic pregnancy (0.2%), 12 (2.0%) stillbirths, and 571 (95.2%) live infants.
Deliveries were more often preterm (29.7 vs. 18.4%; P¼0.01) and the infants had lower
birth weights (2900 vs. 2995 g; P¼0.11) in Zambia compared to South Africa. Thirty-six
infants had birth defects: 13 major and 23 minor. There were more major anomalies
detected in South Africa and more minor ones in Zambia. No neonatal deaths were
attributed to congenital birth defects.
CONCLUSIONS : An Africa-specific, multi-site antiretroviral drug safety registry for pregnant
women is feasible. Different prevalence for preterm delivery, delivery mode, and
birth defect types between women on preconception ART in South Africa and Zambia
highlight the potential impact of health systems on pregnancy outcomes. As countries
establish ART drug safety registries, documenting health facility limitations may be as
essential as the specific ART details.President’s Emergency Plan for AIDS Relief (PEPFAR) through the Centers for
Disease Control and Prevention (CDC) under the terms of Cooperative Agreements U62/CCU123541, 3U2GGH000175–01W1, and 3U2GPS001421.http://www.lww.com/product/?0269-9370hb201
Pregnancy outcomes and birth defects from an antiretroviral drug safety study of women in South Africa and Zambia
To evaluate the safety of combination antiretroviral therapy (ART) in conception and pregnancy in different health systems
- …